Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. However, all patients inev...

Descripción completa

Detalles Bibliográficos
Autor principal: Hirsh, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488453/
https://www.ncbi.nlm.nih.gov/pubmed/26123538
http://dx.doi.org/10.1007/s40259-015-0130-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488453/
https://www.ncbi.nlm.nih.gov/pubmed/26123538
http://dx.doi.org/10.1007/s40259-015-0130-9

Ejemplares similares